What Is the Treatment of Primary Sclerosing Cholangitis?
Primary sclerosing cholangitis (PSC) is a chronic biliary condition. A structured, evidence-based approach guides initial treatment, with specific attention to which therapy is appropriate — and which must be avoided.
Treatment Approach partial overview
Treatment of PSC involves oral bile acid therapy. The specific agent and, critically, the dose range selected determine whether the intervention is beneficial or potentially harmful — certain dose levels are explicitly contraindicated. The complete protocol details which regimen to follow and which to avoid.
Clinical Goals
The primary target is improvement of serum liver tests — in particular alkaline phosphatase — as a surrogate marker of prognosis.
References
DOI: 10.1016/j.jhep.2022.05.011
- UDCA at doses of 15-20 mg/kg/d can be given since it may improve serum liver tests and surrogate markers of prognosis.
- UDCA at doses of 28-30 mg/kg/d should not be given.